Evidence map›Paper›PMID 41405409›Full record

ArticleJournal of chemical information and modeling2026

Consensus Pharmacological Interactions for PLK2 Inhibitor Identification in Colorectal Cancer Treatment.

Yi-Wen Wu, Chun-Lin Yang, Tony Eight Lin, Yun-Hsuan Yeh, Yu-Ting Fang-Chin, Tzu-Ying Sung, Shih-Chung Yen, Jui-Hua Hsieh, Cheng-Chih Chung, Shiow-Lin Pan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of chemical information and modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yi-Wen WuGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Chun-Lin YangGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Tony Eight LinGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0002-6267-0224
Yun-Hsuan YehGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Yu-Ting Fang-ChinGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Tzu-Ying SungGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Shih-Chung YenWarshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong (Shenzhen), Shenzhen, Guangdong 518172, China.
Jui-Hua HsiehDivision of Translational Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Durham, North Carolina 27709, United States.ORCID 0000-0003-1620-1571
Cheng-Chih ChungDivision of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
Shiow-Lin PanGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.
Kai-Cheng HsuGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0002-9022-6673

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PLK2 plays a critical role in cellular stress response, redox regulation, and tumor progression. In colorectal cancer (CRC), elevated PLK2 expression is associated with chemoresistance and poor patient prognosis, making it a compelling target for therapeutic intervention. In this study, we used a structure-based drug discovery strategy to develop a consensus model incorporating pharmacological interactions from various PLK2 structures. This model enhanced the hit rate for identifying inhibitors during virtual screening, increasing the ROC-AUC from 0.906 to 0.930. We then used the model to screen the ChemDiv compound library and identified two novel PLK2 inhibitors. Next, we searched for analogs of the most potent compound and evaluated their activity. Two analogs demonstrated submicromolar inhibition, including Y207-5465 (IC

Indexed as

Antineoplastic AgentsColorectal NeoplasmsProtein Kinase InhibitorsProtein Serine-Threonine KinasesCell Line, TumorDrug DiscoveryDrug Screening Assays, AntitumorHumansMolecular Docking SimulationStructure-Activity RelationshipAntineoplastic AgentsPLK2 protein, humanProtein Kinase InhibitorsProtein Serine-Threonine Kinases

Identifiers

PMID41405409
PMCPMC12801292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.